Compare JPMorgan Chase & Co (JPM) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Nuwellis Inc — how do they compare? JPMorgan Chase & Co trades at $332.4 (market cap $876.09B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: JPMorgan Chase & Co is far larger — about 398222.7× Nuwellis Inc's market cap, and JPMorgan Chase & Co pays a 2% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Nuwellis Inc for 26 Days on average.
| JPM | NUWE | |
|---|---|---|
Market Cap | $876.09B | $2.20M |
Volume | 6,651,143 | 121,544 |
Sector | Financials | Health |
52-Week High | $365.18 | $146.65 |
52-Week Low | $282.84 | $0.68 |
Typical Hold Time | 127 Days | 26 Days |
Enterprise Value | $1.81T | -$1.52M |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $331.42, up 0.04% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $7.59, beating expectations by 36%, with revenue reaching $181.85B in 2025. Analyst consensus remains positive with a $373.18 price target and 52% buy ratings, though technical indicators show selling pressure with RSI levels suggesting potential oversold conditions near key support at $323.
JPMorgan demonstrates robust profitability with 18.43% ROE and reasonable valuation at 14.12 P/E, but faces risks from geopolitical tensions and cybersecurity threats. The stock offers upside to analyst targets with strong institutional support, though negative cash flow trends and bearish technical momentum warrant caution amid macroeconomic uncertainty.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
